Spots Global Cancer Trial Database for enzyme inhibitor
Every month we try and update this database with for enzyme inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | NCT00700206 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome | NCT01459159 | Myelodysplastic... | ezatiostat hydr... | 18 Years - | Telik | |
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | NCT00700206 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT04699188 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Colo... Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | JDQ443 TNO155 tislelizumab | 18 Years - | Novartis |